Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms
Phase 2
18+
Female only
1 site in NY
What this study is about
This Phase 2 study is testing Cabergoline in people with abortion. The primary outcome being measured is Proportion of Participants With Breast Symptoms 4 Days After Abortion or Pregnancy Loss.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cabergoline
oral (Oral Tablet)
Primary: Proportion of Participants With Breast Symptoms 4 Days After Abortion or Pregnancy Loss
Secondary: Participant-Reported Bother/Satisfaction From Breast Symptoms & Serum Prolactin Levels
Reproductive Health